133 related articles for article (PubMed ID: 34044070)
21. KPNB1-mediated nuclear import is required for motility and inflammatory transcription factor activity in cervical cancer cells.
Stelma T; Leaner VD
Oncotarget; 2017 May; 8(20):32833-32847. PubMed ID: 28427184
[TBL] [Abstract][Full Text] [Related]
22. ARID1A loss induces P4HB to activate fibroblasts to support lung cancer cell growth, invasion, and chemoresistance.
Huang R; Wu D; Zhang K; Hu G; Liu Y; Jiang Y; Wang C; Zheng Y
Cancer Sci; 2024 Feb; 115(2):439-451. PubMed ID: 38100120
[TBL] [Abstract][Full Text] [Related]
23. Targeting ARID1A-mutant colorectal cancer: depletion of ARID1B increases radiosensitivity and modulates DNA damage response.
Niedermaier B; Sak A; Zernickel E; Xu S; Groneberg M; Stuschke M
Sci Rep; 2019 Dec; 9(1):18207. PubMed ID: 31796878
[TBL] [Abstract][Full Text] [Related]
24. PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma.
Yamamoto S; Tsuda H; Takano M; Tamai S; Matsubara O
Virchows Arch; 2012 Jan; 460(1):77-87. PubMed ID: 22120431
[TBL] [Abstract][Full Text] [Related]
25. Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers.
Ogiwara H; Takahashi K; Sasaki M; Kuroda T; Yoshida H; Watanabe R; Maruyama A; Makinoshima H; Chiwaki F; Sasaki H; Kato T; Okamoto A; Kohno T
Cancer Cell; 2019 Feb; 35(2):177-190.e8. PubMed ID: 30686770
[TBL] [Abstract][Full Text] [Related]
26. Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer.
Sun D; Tian L; Zhu Y; Wo Y; Liu Q; Liu S; Li H; Hou H
Mol Med; 2020 Aug; 26(1):78. PubMed ID: 32791957
[TBL] [Abstract][Full Text] [Related]
27. ARID1A and CEBPα cooperatively inhibit UCA1 transcription in breast cancer.
Guo X; Zhang Y; Mayakonda A; Madan V; Ding LW; Lin LH; Zia S; Gery S; Tyner JW; Zhou W; Yin D; Lin DC; Koeffler HP
Oncogene; 2018 Nov; 37(45):5939-5951. PubMed ID: 29980791
[TBL] [Abstract][Full Text] [Related]
28. Targeting AURKA-CDC25C axis to induce synthetic lethality in ARID1A-deficient colorectal cancer cells.
Wu C; Lyu J; Yang EJ; Liu Y; Zhang B; Shim JS
Nat Commun; 2018 Aug; 9(1):3212. PubMed ID: 30097580
[TBL] [Abstract][Full Text] [Related]
29. Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer.
Duska LR; Zamarin D; Hamilton E; Oza A; Fleming G; Spira A; Yeku OO; Richardson DL; Walling J; Inokuchi K; Matusow B; Bollag G; Swisher EM
JCO Precis Oncol; 2023 Sep; 7():e2300235. PubMed ID: 37797273
[TBL] [Abstract][Full Text] [Related]
30.
Kawahara N; Yamada Y; Kobayashi H
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070839
[TBL] [Abstract][Full Text] [Related]
31. Targeted sequencing of a specific gene panel detects a high frequency of ARID1A and PIK3CA mutations in ovarian clear cell carcinoma.
Su YF; Tsai EM; Chen CC; Wu CC; Er TK
Clin Chim Acta; 2019 Jul; 494():1-7. PubMed ID: 30851247
[TBL] [Abstract][Full Text] [Related]
32. The Chromatin Remodeling Component Arid1a Is a Suppressor of Spontaneous Mammary Tumors in Mice.
Kartha N; Shen L; Maskin C; Wallace M; Schimenti JC
Genetics; 2016 Aug; 203(4):1601-11. PubMed ID: 27280691
[TBL] [Abstract][Full Text] [Related]
33. The nuclear transporter importin-11 regulates the Wnt/β-catenin pathway and acts as a tumor promoter in glioma.
Ni H; Ji D; Li J; Zhao Z; Zuo J
Int J Biol Macromol; 2021 Apr; 176():145-156. PubMed ID: 33571591
[TBL] [Abstract][Full Text] [Related]
34. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade.
Shen J; Ju Z; Zhao W; Wang L; Peng Y; Ge Z; Nagel ZD; Zou J; Wang C; Kapoor P; Ma X; Ma D; Liang J; Song S; Liu J; Samson LD; Ajani JA; Li GM; Liang H; Shen X; Mills GB; Peng G
Nat Med; 2018 May; 24(5):556-562. PubMed ID: 29736026
[TBL] [Abstract][Full Text] [Related]
35. Uncovering the dosage-dependent roles of Arid1a in gastric tumorigenesis for combinatorial drug therapy.
Loe AKH; Francis R; Seo J; Du L; Wang Y; Kim JE; Hakim SW; Kim JE; He HH; Guo H; Kim TH
J Exp Med; 2021 Jun; 218(6):. PubMed ID: 33822841
[TBL] [Abstract][Full Text] [Related]
36. Arid1a regulates response to anti-angiogenic therapy in advanced hepatocellular carcinoma.
Hu C; Li W; Tian F; Jiang K; Liu X; Cen J; He Q; Qiu Z; Kienast Y; Wang Z; Zhang H; Ji Y; Hu J; Hui L
J Hepatol; 2018 Mar; 68(3):465-475. PubMed ID: 29113912
[TBL] [Abstract][Full Text] [Related]
37. Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogramming.
Suryo Rahmanto Y; Shen W; Shi X; Chen X; Yu Y; Yu ZC; Miyamoto T; Lee MH; Singh V; Asaka R; Shimberg G; Vitolo MI; Martin SS; Wirtz D; Drapkin R; Xuan J; Wang TL; Shih IM
Nat Commun; 2020 Jun; 11(1):2717. PubMed ID: 32483112
[TBL] [Abstract][Full Text] [Related]
38. METTL8 mRNA Methyltransferase Enhances Cancer Cell Migration via Direct Binding to ARID1A.
Lee SA; Lee KH; Kim H; Cho JY
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34063990
[TBL] [Abstract][Full Text] [Related]
39. The Tumor Suppressor ARID1A Controls Global Transcription via Pausing of RNA Polymerase II.
Trizzino M; Barbieri E; Petracovici A; Wu S; Welsh SA; Owens TA; Licciulli S; Zhang R; Gardini A
Cell Rep; 2018 Jun; 23(13):3933-3945. PubMed ID: 29949775
[TBL] [Abstract][Full Text] [Related]
40. mRNA Display Identifies Potent, Paralog-Selective Peptidic Ligands for ARID1B.
Cremosnik GS; Mesrouze Y; Zueger P; Furkert D; Grandjean F; Argoti D; Mermet-Meillon F; Bauer MR; Brittain S; Rogemoser P; Yang W; Giovannoni J; McGregor L; Tang J; Knapp M; Holzinger S; Buhr S; Muller L; Leder L; Xie L; Fernandez C; Nieto-Oberhuber C; Chène P; Galli GG; Sesterhenn F
ACS Chem Biol; 2024 May; 19(5):1142-1150. PubMed ID: 38655884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
